NCL Technology Ventures

About The Fund

NCL Technology Ventures is a specialist healthcare investment manager and advisory boutique, headquartered in London, United Kingdom, with satellite offices in the United States. Founded in 2010, the firm invests transformational equity capital in innovative and disruptive technology small and medium-sized enterprises (SMEs) within the life sciences sector, focusing primarily on oncology. They identify companies at the commercialization stage and provide them with essential resources and institutional investment capital, aiming to bridge the funding gap and foster high-performing ventures. With a clear investment thesis to capitalize on the modernization of healthcare as a significant growth driver in the 21st century, NCL Technology Ventures harnesses the potential of companies that employ innovation and technological advancements to prevent, treat, and cure various conditions. They target entrepreneurs pioneering new methods to address future health challenges and create valuable businesses. The fund has a distinct investment criterion, with both minimum and maximum investment amounts set at £2,100,000. Through their portfolio, NCL Technology Ventures supports a diverse range of companies involved in areas like inflammatory disease remission, autoimmune treatments, novel immunotherapies, personalized cancer therapies, facial data analysis, and autoimmune and allergic disease reversal, among others. NCL's team comprises experienced investment professionals and entrepreneurs with extensive industry expertise, bringing together multiple generations of venture stage investing, business management, and leadership.